PB 37 of 2024 National Health (April 2024 Price Reductions) (Exercise of Ministerial discretion) Determination (No.2) 2024 National Health Act 1953 I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged, delegate of the Minister for Health and Aged Care make this determination under subsection 99ACF(3) of the National Health Act 1953. Dated 27 March 2024 NIKOLAI TSYGANOV Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Health Resourcing Group Department of Health and Aged Care 1 Name of Determination (1) This instrument is the National Health (April 2024 Price Reductions) (Exercise of Ministerial discretion) Determination (No.2) 2024. (2) This instrument may also be cited as PB 37 of 2024. 2 Commencement (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms. Commencement information Column 1 Column 2 Column 3 Provisions Commencement Date/Details 1. The whole of this instrument The day this instrument is registered. Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument. (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument. 3 Definition Note: A number of expressions used in this instrument are defined in Part VII the Act. In this instrument: Act means the National Health Act 1953. reduction day in this instrument refers to 1 April 2024. 4 Authority This instrument is made under subsection 99ACF(3) of the Act. 5 Brand of pharmaceutical item not subject to a price reduction I determine, under paragraph 99ACF(3)(a) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 1 is not reduced under a provision mentioned in item 2A in subsection 99ACF(1) of the Act, as appropriate, in relation to the reduction day. Schedule 1— Brands of pharmaceutical items with approved ex-manufacturer price not reduced Column 1 Column 2 Item Brand of Pharmaceutical Item Drug Form Manner of administration Brand(s) 1 Dulaglutide Injection 1.5 mg in 0.5 mL single dose pre-filled pen Injection Trulicity 2 Trifluridine with tipiracil Tablet containing 15 mg trifluridine with 6.14 mg tipiracil (as hydrochloride) Oral Lonsurf 15/6.14 3 Trifluridine with tipiracil Tablet containing 20 mg trifluridine with 8.19 mg tipiracil (as hydrochloride) Oral Lonsurf 20/8.19